ClinicalTrials.gg
No longer availableNCT06574997Updated Oct 2, 2026

Expanded Access Program for RP in Adults

An expanded access record providing OCU400 in Retinitis Pigmentosa, sponsored by Ocugen. No longer available at 5 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Ocugen · Expanded access

How we know

Updated Oct 2, 2026Now No longer availableGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Individual patients · Intermediate-size population
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 119 studies in Retinitis Pigmentosa with a site in United States — 20 open to participants now, 43 under way, 6 of them phase 3. Retinitis Pigmentosa · United States.

Other kind
Only one
of the 119
Registered
110th of 119
by date

Among the 119 studies in Retinitis Pigmentosa with a site in United States, this one is the only one of another kind, and was the 110th registered.

Retinitis Pigmentosa

281 studies on the registry are indexed under Retinitis Pigmentosa; 74 are open to participants now.

Browse Retinitis Pigmentosa studies →

Open to participants now

20 of the 119 studies in Retinitis Pigmentosa with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Retinitis Pigmentosa studies recruiting now, 38 (76%) set no upper age limit and 6 (12%) stop at 75 or younger; 16 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 119 studies in Retinitis Pigmentosa with a site in United States, or all of them as a file.
02

Study summary

This intermediate-size patient population expanded access program is to provide access to investigational product OCU400 for up to 75 patients with Retinitis Pigmentosa (RP) outside of the ongoing clinical trial Phase 3 program for patients who do not have access to alternative Food and Drug Administration (FDA)-approved products for treatment of the disease.

Read the detailed description

This expanded access protocol provides access to OCU400 for a subset of patients. Subjects will undergo specific ocular testing included in the study. Subjects will follow-up with physical examination, review of concomitant medication, blood work and ocular examinations for up to 52 weeks (about 12 months) post dosing.

03

Conditions studied

  • Retinitis Pigmentosa

Browse trials for

Keywords

  • Retinitis Pigmentosa
  • Modifier Gene Therapy
  • Modified Gene Therapy
  • RHO
  • RP
  • NR2E3
  • Subretinal Injection
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females ≥18 years of age at the time of .
  2. Confirmed clinical and CLIA certified genetic diagnosis of RP (except subjects with AD-NR2E3 mutation)
  3. Presence of photoreceptors as determined by spectral-domain optical coherence tomography (SD-OCT).

Exclusion criteria

Exclusion Criteria:

  1. Subject lacks evidence of outer nuclear layer, i.e., containing the nuclei of the retinal photoreceptors as determined by SD- OCT.
  2. Considered unsuitable for any reason that may either place the subject at increased risk during participation or interfere with the interpretation of the study outcomes by the Investigator, or the Sponsor after reviewing the subject medical history and condition.
  3. Previous treatment with a gene-therapy or cell therapy product, excluding OCU400.
  4. Previous treatment with any drug or device within one year, excluding OCU400.
  5. Any for subretinal injection.
  6. Cataract surgery within 3 months. YAG capsulotomy within 1 month. Any other intraocular surgery within 6 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Access details

Study type
Expanded access
Access type
Individual patients · Intermediate-size population

Available treatment

  • DrugOCU400

    Participants will receive a subretinal injection of OCU400 modifier gene therapy product.

06

Where to request access

5 sites
  • Associated Retina Consultants
    Phoenix, Arizona 85020, United States
  • Advanced Research
    Deerfield Beach, Florida 33064, United States
  • Erie Retina Research
    Erie, Pennsylvania 16507, United States
  • Valley Retina Institute
    McAllen, Texas 78503, United States
  • Gundersen Health
    La Crosse, Wisconsin 54601, United States
07

Updates

1 registry update since Sep 25, 2026
Status
Available→No longer available
changed Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Available→No longer available
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

08

Registry details

Key details

Study ID
NCT06574997
Lead sponsor
Ocugen
Responsible party
Sponsor
First posted
Aug 28, 2024
Last update
Oct 2, 2026

Study contacts

Jennifer Henrick, RN, MS
study director · Ocugen., Inc.
Mohamed Genead, MD
study chair · Ocugen., Inc
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion